Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos and Bayer Enter Target Discovery Collaboration

NEW YORK, Dec. 16 (GenomeWeb News) - Galapagos Genomics has entered into a collaboration with Bayer HealthCare to discover and validate novel drug targets, Galapagos said today.

Galapagos will design cellular assays in disease areas of interest to Bayer, and then use its SilenceSelect collection of adenoviruses with siRNA based knock-down sequences, along with its FLeXSelect collection of adenoviruses with full-length genes from druggable gene classes, to identify and validate targets.

Bayer has the exclusive right to select validated targets for drug development in return for upfront payments, research funding, and milestones. Further financial terms were not disclosed.